Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
3(33%)
Results Posted
50%(1 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_1
1
11%
Ph phase_3
1
11%
Ph phase_2
7
78%

Phase Distribution

1

Early Stage

7

Mid Stage

1

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
7(77.8%)
Phase 3Large-scale testing
1(11.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

3

trials recruiting

Total Trials

9

all time

Status Distribution
Active(6)
Completed(2)
Terminated(1)

Detailed Status

Recruiting3
Not yet recruiting3
Completed2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
3
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (11.1%)
Phase 27 (77.8%)
Phase 31 (11.1%)

Trials by Status

recruiting333%
not_yet_recruiting333%
completed222%
terminated111%

Recent Activity

3 active trials
Showing 5 of 9
recruitingphase_2

Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

NCT07259317
not_yet_recruitingphase_2

Gemcitabine vs Paclitaxel in Caribbean Women of African Ancestry With Metastatic Triple-Negative Breast Cancer

NCT07528768
recruitingphase_2

Low Dose Epcoritamab Plus GemOx in R/R DLBCL

NCT07451652
not_yet_recruitingphase_2

Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma

NCT07498907
completedphase_2

Gemcitabine as Maintenance Treatment for Diffuse Pleural Mesothelioma

NCT07411144
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT07259317Phase 2

Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

Recruiting
NCT07528768Phase 2

Gemcitabine vs Paclitaxel in Caribbean Women of African Ancestry With Metastatic Triple-Negative Breast Cancer

Not Yet Recruiting
NCT07451652Phase 2

Low Dose Epcoritamab Plus GemOx in R/R DLBCL

Recruiting
NCT07498907Phase 2

Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma

Not Yet Recruiting
NCT07411144Phase 2

Gemcitabine as Maintenance Treatment for Diffuse Pleural Mesothelioma

Completed
NCT07272109Phase 3

Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes

Not Yet Recruiting
NCT05141149Phase 1

First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer

Recruiting
NCT04602078Phase 2

Study of Atezolizumab Combined With Split-dose Gemcitabine Plus Cisplatin in Urothelial Carcinoma

Completed
NCT00550004Phase 2

Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine

Terminated

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9